Browsing by Author "Toprak O.B."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    COVID-19: vaccination vs. hospitalization
    (Springer Science and Business Media Deutschland GmbH, 2022) Uzun O.; Akpolat T.; Varol A.; Turan S.; Bektas S.G.; Cetinkaya P.D.; Dursun M.; Bakan N.; Ketencioglu B.B.; Bayrak M.; Baris S.A.; Guner R.; Gunal O.; Nural S.; Deniz P.P.; Toprak O.B.; Ozkan G.; Gumus A.; Kerget F.; Ercelik M.; Ataoglu O.; Yuksel A.; Ates G.; Kutsoylu O.E.; Kose N.; Kizilirmak D.; Keskin S.; Gultekin O.; Coskun N.; Yilmaz E.S.; Uslu S.; Basyigit İ.; Ergan B.; Deveci F.; Yakar M.N.; Zuhur C.; Sagcan G.; Yuce Z.T.; Kuluozturk M.; Sezgin M.E.; Sezgin E.N.A.; Havlucu Y.; Cuhadaroglu C.; Kilinc O.; Boyaci H.; Altunay H.; Akti M.; Dursun Z.B.; Kalem A.K.; Isik S.A.; Akyildiz L.; Aykac N.; Almaz M.S.; Kokturk N.; Itil O.
    Objective: Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting: Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods: We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results: We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion: Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination. © 2022, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
  • No Thumbnail Available
    Item
    COVID-19: booster(s) vs. hospitalization and Intensive Care Unit admission
    (Verduci Editore s.r.l, 2023) Toprak O.B.; Akpolat T.; Uzun O.; Pinar Deniz P.; Kokturk N.; Varol A.; Guzel E.; Ercelik M.; Gultekin O.; Guner R.; Turan S.; Gökbulut Bektaş Ş.; Coskun N.; Bakan N.; Nuri Yakar M.; Eren Kutsoylu O.; Ergan B.; Argun Bariş S.; Başyiğit İ.; Boyaci H.; Çetinkaya F.; Çolak H.; Aykac N.; Baran Ketencioğlu B.; Türe Yüce Z.; Akkaya Isik S.; Serap Yilmaz E.; Karaoğlanoğlu S.; Berik Safci S.; Ozkan G.; Kose N.; Kizilirmak D.; Havlucu Y.; Nural S.; Kerget F.; Sunal Ö.; Yuksel A.; Bestepe Dursun Z.; Deveci F.; Kuluozturk M.; Ataoglu O.; Dursun M.; Keskin S.; Emin Sezgin M.; Aktepe Sezgin E.N.; Eser F.; Akyildiz L.; Selim Almaz M.; Kayaaslan B.; Hasanoğlu İ.; Bayrak M.; Gümüş A.; Sağcan G.; Cuhadaroglu C.; Kucuk H.; Onyilmaz T.; Mete B.; Kilinc O.; Oya Itil B.
    OBJECTIVE: As the pandemic continues, different vaccine protocols have been implemented to maintain the protection of vaccines and to provide protection against new variants. The aim of this study was to assess hospitalized patients' vaccination status and document the efficacy of boosters. PATIENTS AND METHODS: The patients that were hospitalized due to COVID-19 were enrolled from 28 hospitals in Turkey for five months from September 2021. 5,331 confirmed COVID-19 patients from collaborating centers were randomly enrolled to understand/estimate the distribution of vaccination status in hospitalized patients and to compare the efficacy of vaccination/booster protocols. RESULTS: 2,779 men and 2,552 women of which 2,408 (45.2%) were admitted to Intensive Care Units participated in this study. It was found that the highest risk reduction for all age groups was found in groups that received 4 doses. Four doses of vaccination for every 3.7 people under 50 years of age, for every 5.7 people in the 50-64 age group, and for every 4.3 people over 65 years of age will prevent 1 patient from being admitted to intensive care. Regardless of the type of vaccine, it was found that the risk of ICU hospitalization decreased in those who were vaccinated compared to those who were not vaccinated. Regardless of the type of vaccine, the ICU risk was found to decrease 1.25-fold in those who received 1 or 2 doses of vaccine, 1.18-fold in those who received 3 doses, and 3.26-fold in those who received 4 doses. CONCLUSIONS: The results suggested that the addition of a fourth dose is more effective in preventing intensive unit care even in disadvantaged. © 2023 Verduci Editore s.r.l. All rights reserved.
  • No Thumbnail Available
    Item
    Clinical Course of Coronavirus disease 2019 C-19 in Patients with Bronchiectasis
    (AVES, 2024) Edis E.Ç.; Çilli A.; Kızılırmak D.; Coşkun A.Ş.; Sayıner A.; Çiçek S.; Gülmez İ.; Ağca M.Ç.; Çağlayan B.; Özçelik N.; Köktürk N.; Ocaklı B.; Uçan E.S.; Günlüoğlu G.; Niksarlıoğlu Y.; Zamani A.; Berk S.; Barış S.A.; Başyiğit İ.; Gülhan P.Y.; Kabak M.; Çolak M.; Toprak O.B.; Berk H.; Oğuzülgen K.; Demirdöğen E.; Eyüboğlu F.Ö.; Havlucu Y.; Babayiğit C.
    OBJECTIVE: Coronavirus disease 2019 (COVID-19) has affected the whole world and caused the death of more than 6 million people. The disease has been observed to have a more severe course in patients with chronic lung diseases. There are limited data regarding COVID-19 in patients with bronchiectasis. The aim of this article is to investigate the course of COVID-19 and factors affecting the clinical outcome in patients with bronchiectasis. MATERIAL AND METHODS: This study was conducted using the Turkish Adult Bronchiectasis Database (TEBVEB) to which 25 centers in Türkiye contributed between March 2019 and January 2022. The database consisted of 1035 patients, and COVID-19-related data were recorded for 606 patients. RESULTS: One hundred nineteen (19.6%) of the bronchiectasis patients (64 female, mean age 57.3 ± 13.9) had COVID-19. Patients with bronchiectasis who developed COVID-19 more frequently had other comorbidities (P = .034). They also more frequently had cystic bron-chiectasis (P = .009) and their Bronchiectasis Severity Index was significantly higher (P = .019). Eighty-two (68.9%) of the patients who had COVID-19 were followed up in the outpatient clinic, 27 (22.7%) in the inpatient ward and 10 (8.4%) patients in the intensive care unit. There tended to be a higher percentage of males among patients admitted to the hospital (P = .073); similarly, the mean age of the patients admitted to the hospital was also higher (60.8 vs 55.8 years for the outpatients), but these differences did not reach statistical significance (P = .071). CONCLUSION: In conclusion, this study showed that severe bronchiectasis, presence of cystic bronchiectasis and worse Bronchiectasis Severity Index are associated with the development of COVID-19, but not with the severity of infection. © 2024, AVES. All rights reserved.